Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
777发布了新的文献求助10
1秒前
郭思凡发布了新的文献求助30
2秒前
不得发布了新的文献求助10
2秒前
吴逸彪发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
4秒前
4秒前
黄志东完成签到,获得积分10
5秒前
7秒前
8秒前
8秒前
9秒前
qiu发布了新的文献求助10
9秒前
李健应助傅礼貌采纳,获得10
9秒前
amazing39发布了新的文献求助10
11秒前
BW完成签到,获得积分10
12秒前
星辰大海应助yltstt采纳,获得20
14秒前
平平发布了新的文献求助10
14秒前
四夕发布了新的文献求助10
14秒前
PiaoGuo完成签到,获得积分10
17秒前
Ava应助方糖采纳,获得10
17秒前
18秒前
Ash完成签到,获得积分10
18秒前
amazing39完成签到,获得积分10
19秒前
19秒前
20秒前
彭于晏应助威武香水采纳,获得10
20秒前
黄志东发布了新的文献求助10
21秒前
23秒前
稚初发布了新的文献求助10
23秒前
今后应助Bbg采纳,获得10
24秒前
郭思凡完成签到,获得积分10
25秒前
998877剑指发布了新的文献求助10
26秒前
wewe发布了新的文献求助10
28秒前
junjunjun发布了新的文献求助10
29秒前
任性的怀柔完成签到,获得积分20
29秒前
30秒前
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
卤化钙钛矿人工突触的研究 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Malcolm Fraser : a biography 700
Handbook of Optical Systems,Volume 6:Advanced Physical Optics 666
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6514352
求助须知:如何正确求助?哪些是违规求助? 8307742
关于积分的说明 17753036
捐赠科研通 5616220
什么是DOI,文献DOI怎么找? 2924621
邀请新用户注册赠送积分活动 1901566
关于科研通互助平台的介绍 1763060